Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date

Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 10, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2026 (the Company's fiscal Q1 2027). All dollar amounts in this news release are in US dollars unless specified otherwise.